Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Jul 20, 2016 4:48pm
100 Views
Post# 25070171

RE:RE:RE:RE:AGM nearing

RE:RE:RE:RE:AGM nearingHey Jkj. Good points.

Lack of the NASDAQ listing remains a real draw back and there seems to be no motivation to get it.

I remain very curious as to why Don hired a VP of IR back a few months ago! We know which way the ship is pointed and that is to complete phase 3 BETonMACE and so far it has been steady sailing and we are 6 months into the trial and the seas seem smooth with good wind at Don's back. BoM results won't be in until late 2018. We have a little more than 2 full years to wait. So what is the VP of IR going to be doing? 

It does seem to suggest that Don feels the share price in undervalued i.e. he needs good coverage from highly respected independent analysts??? I sure don't know. Could it relate to the next regional deal?

Oh well, the good science is progressing well at both Zenith and RVX and that is what counts.
GLTA
Cheers
Toinv
Bullboard Posts